Find a Clinical Trial
|Protocol||Trial Name and Objective|
PROGNOSTIC FACTORS FOR INCIDENTAL GALLBLADDER CANCER
The goal of this study is to evaluate whether age, sex, presence of inflammation, grade, stage, or inadvertent gallbladder perforation affect survival of patients with incidental gallbladder cancer
Retrospective Comparative Analysis of Hematologic Toxicities in Patients Receiving Chemo-Radiotherapy in Rectal Cancers Versus Chemotherapy in Colon Cancers.
To quantify bone marrow toxicity after radiation therapy in rectal cancer patients compared to bone marrow toxicity without radiation therapy in colon cancer patients.
Retrospective and Prospective review of Patients with Metastatic colorectal cancer with ≥ 24 month survival
Review the characteristics and the treatment of all patients with metastatic colon cancer who have survived more than two years after diagnosis of metastatic disease.
Comparative Analysis of Duodenal reconstruction with Roux-en-Y versus Primary Closure post Partial Duodenectomy - A Retrospective Chart Review
The optimal method of duodenal reconstruction following resection for oncologic surgery is not clear. We aim to clarify this through an analysis of outcomes following our experience with surgical reconstruction of the duodenum
Couple-Focused Intervention for Colorectal Cancer Screening
Specific Aim 1:To compare the efficacy of three interventions: Enhanced Couple-Tailored Intervention (E-CTI), an Enhanced Couples' Generic Intervention (E-GCI), and a Generic Print Intervention (GP) on couples' CRCS.
Molecular Analysis of Rare Tumors Subclasses
The overall aim is to determine what set of genomic alterations are present in ampullary cancers. If we find that, similar to our index case, activating mutations in tyrosine kinases are present in a significant subset of these cancers, this finding may lead to novel therapeutic strategies for these cancers.
NCI/CTEP #9571: A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinic) and Cyclosporin A (CsA) in Patients with Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
Primary Objective: To determine the maximum tolerated dose (MTD)and dose-limiting toxicities (DLT) of the combination of AZD6244 and cyclosporin A in adult patients with advanced solid tumors.
TO-TAS-102-401: AN OPEN-LABEL EXPANDED ACCESS STUDY OF TAS-102 IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO OR FAILING STANDARD CHEMOTHERAPY
TO provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated, in the time period between completion of the Phase 3 clinical trial protocol TPU-TAS-102-301 and prior to TAS-102 being commercially available. This is an unmet clinical need
CALGB C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy (FOLFOX) or standard chemotherapy with 3 years of celecoxib 400 mg daily.
CALGB 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Primary: 1) To induce a pCR rate of 20% in PET scan responders treated with either induction FOLFOX or carboplatin/paclitaxel, who then cross over to the other regimen during radiotherapy
DEK-DKK1-P102: A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors
Neogenix0901: A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody in Adults with Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer after Standard Therapy
Determine the safety and tolerability of escalating doses of NPC-1C (NEO-102) monoclonal antibody therapy in subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer or metastatic colorectal cancer that express NPC-1C target on tumor;